Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464525 | 0.85 | CTSK (0.48) | CTSKCTSSITGB3ITGA2BSIRT6 | |
| SCHEMBL8143993 | 0.85 | CTSK (0.48) | CTSKCTSSITGB3ITGA2BSIRT6 | |
| SCHEMBL15821190 | 0.80 | CTSK (0.46) | CTSKCTSSSLC6A5ITGB3ITGA2B | |
| SCHEMBL3731098 | 0.78 | ITGB3 (0.48) | CTSKCTSSITGB3ITGA2B | |
| SCHEMBL30466181 | 0.76 | CTSK (0.50) | CTSKCTSSITGB3ITGA2BSIRT6 | |
| SCHEMBL31394931 | 0.76 | CTSK (0.50) | CTSKCTSSITGB3ITGA2BSIRT6 | |
| SCHEMBL9439085 | 0.75 | CTSK (0.58) | CTSKCTSS | |
| SCHEMBL38652797 | 0.75 | CTSK (0.60) | CTSKCTSS | |
| SCHEMBL29411192 | 0.74 | CYP1A2 (0.54) | CTSKCTSSITGB3ITGA2B | |
| SCHEMBL6751878 | 0.74 | FOLH1 (0.51) | CTSKCTSSSLC6A5ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771206-B1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS GMBH (DE) | 2018-04-11 | — | — | EP | disclosed |
| US-20170036990-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9486538-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS GMBH (DE) | 2016-11-08 | — | — | US | disclosed |
| US-9387262-B2 | Coated lipid complexes and their use | SILENCE THERAPEUTICS GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| EP-2992902-A1 | LIPID COMPLEXES COATED WITH PEG AND THEIR USES | Silence Therapeutics GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-20150359906-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2015-12-17 | — | — | US | disclosed |
| US-9125820-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| EP-1830888-B1 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS GMBH (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20150031752-A1 | COATED LIPID COMPLEXES AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20140329885-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS GMBH (DE) | 2014-11-06 | — | — | US | disclosed |
| US-20110294871-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-8017804-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS AG (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20100062967-A1 | COATED LIPID COMPLEXES AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2010-03-11 | — | — | US | disclosed |
| WO-2006069782-A9 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2009-04-30 | — | — | WO | disclosed |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | SILENCE THERAPEUTICS AG (DE) | 2008-11-06 | — | — | US | disclosed |
| CN-101287497-A | Lipid complexes coated with peg and their use | SILENCE THERAPEUTICS AG (DE) | 2008-10-15 | — | — | CN | disclosed |
| EP-1830888-A2 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | Silence Therapeutics AG (DE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1771206-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | atugen AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006069782-A2 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS AG. (DE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005105152-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | ATUGEN AG (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294871-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, SGMS1 | CTSK 2810/4885CTSS 2754/4885SLC6A5 3335/4885 |
| US-20100062967-A1 | COATED LIPID COMPLEXES AND THEIR USE | HDLBP, NR1H3, CETP | CTSK 4550/4885CTSS 4557/4885SLC6A5 4838/4885 |
| US-20170036990-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | CTSK 2191/4885CTSS 2384/4885SLC6A5 3378/4885 |
| US-20150359906-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | CTSK 2191/4885CTSS 2384/4885SLC6A5 3378/4885 |
| US-20150031752-A1 | COATED LIPID COMPLEXES AND THEIR USE | HDLBP, NR1H3, CETP | CTSK 4550/4885CTSS 4557/4885SLC6A5 4838/4885 |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | MGLL, LIPA, SGMS1 | CTSK 2886/4885CTSS 2739/4885SLC6A5 3355/4885 |
| US-20140329885-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | CTSK 2191/4885CTSS 2384/4885SLC6A5 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.